Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from December 2022.

Interesting empirical studies, policy analyses, and editorials on health law and policy issues from December 2022.

If pharma giants truly are committed to addressing vaccine inequity, just building manufacturing capacity in Africa might not be enough.

An explanation of the key patents at stake in the intellectual property dispute between Moderna and Pfizer/BioNTech over COVID-19 vaccines.

The top ten most-read articles published on Bill of Health in 2022.

Interesting empirical studies, policy analyses, and editorials on health law and policy issues from November 2022.

The consequences that result from state bans and restrictions on medication abortion represent just one example of “healthcare federalism.”

Despite Italy being the fifth largest country in the EU for pharmaceutical expenditures, total revenue is dropping.

The future of public health in an “RNA world” is on trial in a trade secrecy dispute worth $950 million.

The Truth Pill is a monumental work that convincingly shows that drug regulation is but a myth in India.

Interesting empirical studies, policy analyses, and editorials on health law and policy issues from October 2022.
